# US 2013/0296320 A1 · Novel bicyclic compound or salt thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0296320 A1
- Document ID: US20130296320A1
- Status: Published application
- Kind: A1
- Application number: 13/978,613
- Filed: 2012-01-06
- Published: 2013-11-07
- Earliest claimed: 2011-01-07
- Assignees: Taiho Pharmaceutical Co., Ltd.
- Inventors: Makoto Kitade; Satoshi Yamashita; Shuichi Ohkubo
- Web page: https://patentgrep.com/patent/US20130296320A1

## CPC

- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/497: containing further heterocyclic rings
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- C07D 403/14: containing three or more hetero rings
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a novel bicyclic compound which has an HSP90 inhibitory effect and a carcinostatic effect. Also provided is a pharmaceutical agent which is based on the HSP90 inhibitory effect and is useful in the prevention and/or treatment of a disease involving HSP90, particularly, cancer. The present invention provides a compound represented by the following general formula (I) or a salt thereof wherein at least one of X1, X2, X3, and X4 represents N or N-oxide and the rest thereof are the same or different and each represent C—R2; any one or two of Y1, Y2, Y3, and Y4 represent C—R4 and the rest thereof are the same or different and each represent CH or N; R1 represents an optionally substituted monocyclic or bicyclic unsaturated heterocyclic group having 1 to 4 heteroatoms selected from N, S, and O; R2 represents a hydrogen atom, an optionally substituted alkyl group having 1 to 6 carbon atoms etc.; R3 represents a hydrogen atom, —CO—R5 etc.; R4 represents a hydrogen atom, —CO—R6, —N(R7)(R8) etc.; R5 represents a hydroxyl group, an amino group etc.; R6 represents a hydroxyl group etc.; R7 and R8 are the same or different and each represent a hydrogen atom, an optionally substituted alkyl group having 1 to 6 carbon atoms etc.; and R9 represents an optionally substituted cycloalkyl group having 3 to 7 carbon atoms etc.

## Claims

### Claim 1

A compound represented by formula (I) or a salt thereof:
wherein at least one of X1, X2, X3, and X4 represents N or N-oxide and the rest thereof are the same or different and each represent C—R2;
any one or two of Y1, Y2, Y3, and Y4 represent C—R4 and the rest thereof are the same or different and each represent CH or N;
R1 represents an optionally substituted monocyclic or bicyclic unsaturated heterocyclic group having 1 to 4 heteroatoms selected from the group consisting of N, S, and O;
R2 represents a hydrogen atom, an optionally substituted alkyl group having 1 to 6 carbon atoms, an optionally substituted cycloalkyl group having 3 to 7 carbon atoms, or an optionally substituted alkenyl group having 2 to 6 carbon atoms;
R3 represents a cyano group or —CO—R5;
R4 represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, —CO—R6, —N(R7)(R8), or —S—R9;
R5 represents a hydroxyl group, an amino group, or an optionally substituted alkylamino group having 1 to 6 carbon atoms;
R6 represents a hydroxyl group, an amino group optionally having a hydroxyl group, or an optionally substituted alkylamino group having 1 to 6 carbon atoms;
R7 and R8 are the same or different and each represent a hydrogen atom, an optionally substituted alkyl group having 1 to 6 carbon atoms, an optionally substituted cycloalkyl group having 3 to 7 carbon atoms, an optionally substituted aromatic hydrocarbon group, an optionally substituted saturated heterocyclic group, or an optionally substituted unsaturated heterocyclic group, or R7 and R8 together form a saturated heterocyclic group together with the nitrogen atom bonded thereto; and
R9 represents an optionally substituted cycloalkyl group having 3 to 7 carbon atoms, or an optionally substituted aromatic hydrocarbon group.

### Claim 2 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein R1 is an optionally substituted monocyclic or bicyclic 5- to 10-membered unsaturated heterocyclic group having 1 to 3 heteroatoms selected from the group consisting of N, S, and O.

### Claim 3 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein X2 is C—R2, at least one of X1, X3 and X4 is N or N-oxide and each of the rest of X1, X3 and X4 is CH.

### Claim 4 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein R2 is a hydrogen atom; an alkyl group having 1 to 6 carbon atoms and optionally having a substituent selected from the group consisting of a halogen atom and a saturated heterocyclic group; or an optionally substituted cycloalkyl group having 3 to 7 carbon atoms.

### Claim 5 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein R3 is a cyano group or —CO—R5 wherein R5 is an amino group or an alkylamino group having 1 to 6 carbon atoms and optionally having an alkylamino group having 1 to 6 carbon atoms, wherein an alkyl moiety is optionally substituted by a hydroxyl group.

### Claim 6 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein R4 is a hydrogen atom, a halogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, or —N(R7)(R8)
wherein
R7 is a hydrogen atom, and
R8 is a hydrogen atom; an alkyl group having 1 to 6 carbon atoms and optionally having a substituent selected from the group consisting of an alkoxy group having 1 to 6 carbon atoms, a cycloalkyl group having 3 to 7 carbon atoms, a saturated heterocyclic group, and an unsaturated heterocyclic group; a cycloalkyl group having 3 to 7 carbon atoms and optionally having a substituent selected from a hydroxyl group, an amino group, an aminoacyloxy group, and a saturated heterocyclic acyloxy group; or a monocyclic or bicyclic saturated heterocyclic group having 1 to 4 heteroatoms selected from the group consisting of N, S, and O and optionally having an alkyl group having 1 to 6 carbon atoms.

### Claim 7 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein:
Y4 is C—R4 or N and each of Y1 to Y3 is CH, or
each of Y2 to Y4 is CH and Y1 is C—R4.

### Claim 8 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein:
X2 is C—R2, X4 is CH, at least one of X1 and X3 is N or N-oxide and the other of X1 and X3 is CH,
Y4 is C—R4 or N and each of Y1 to Y3 is CH, or each of Y2 to Y4 is CH and Y1 is C—R4,
R1 is an optionally substituted monocyclic or bicyclic unsaturated heterocyclic group having 1 to 4 heteroatoms selected from the group consisting of N, S, and O,
R2 is a hydrogen atom; an alkyl group having 1 to 6 carbon atoms and optionally having a halogen atom; or a cycloalkyl group having 3 to 7 carbon atoms,
R3 is —CO—R5 wherein R5 is an amino group, and
R4 is a halogen atom, an alkyl group having 1 to 6 carbon atoms, or —N(R7)(R8)
wherein
R7 is a hydrogen atom, and
R8 is a hydrogen atom; an alkyl group having 1 to 6 carbon atoms and optionally having a substituent selected from the group consisting of an alkoxy group having 1 to 6 carbon atoms, a cycloalkyl group having 3 to 7 carbon atoms, a saturated heterocyclic group, and an unsaturated heterocyclic group; a cycloalkyl group having 3 to 7 carbon atoms and optionally having a substituent selected from a hydroxyl group, an amino group, an aminoacyloxy group, and a saturated heterocyclic acyloxy group; or a monocyclic or bicyclic saturated heterocyclic group having 1 to 4 heteroatoms selected from N, S, and O and optionally having an alkyl group having 1 to 6 carbon atoms.

### Claim 9 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein
X2 is C—R2, X4 is CH, at least one of X1 and X3 is N or N-oxide and the other of X1 and X3 is CH,
Y4 is C—R4 or N and each of Y1 to Y3 is CH, or each of Y2 to Y4 is CH and Y1 is C—R4,
R1 is (i) a monocyclic 5- to 6-membered unsaturated heterocyclic group having 1 to 3 heteroatoms selected from the group consisting of N, S, and O and optionally having a substituent selected from the group consisting of an alkyl group having 1 to 6 carbon atoms; an alkylamino group having 1 to 6 carbon atoms; an acylamino group having 1 to 6 carbon atoms and optionally having a hydroxyl group; and an unsaturated heterocyclic group optionally having a substituent selected from the group consisting of an alkyl group having 1 to 6 carbon atoms and a halogenoalkyl group having 1 to 6 carbon atoms, or (ii) a bicyclic 9- to 10-membered unsaturated heterocyclic group having 1 to 3 heteroatoms selected from the group consisting of N, S, and O and optionally having a substituent selected from the group consisting of an alkyl group having 1 to 6 carbon atoms and an acyl group having 1 to 6 carbon atoms,
R2 is a hydrogen atom; an alkyl group having 1 to 6 carbon atoms and optionally having a halogen atom; or a cycloalkyl group having 3 to 7 carbon atoms,
R3 is —CO—R5 wherein R5 is an amino group, and
R4 is a halogen atom, an alkyl group having 1 to 6 carbon atoms, or —N(R7)(R8)
wherein
R7 is a hydrogen atom, and
R8 is a hydrogen atom; an alkyl group having 1 to 6 carbon atoms and optionally having a substituent selected from the group consisting of an alkoxy group having 1 to 6 carbon atoms, a cycloalkyl group having 3 to 7 carbon atoms, a saturated heterocyclic group, and an unsaturated heterocyclic group; or a cycloalkyl group having 3 to 7 carbon atoms and optionally having a substituent selected from the group consisting of a hydroxyl group, an amino group, an aminoacyloxy group, and a saturated heterocyclic acyloxy group.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising the compound according to claim 1 or a salt thereof, and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 1)

An agent suitable for prevention or treatment of a disease involving HSP90, comprising the compound according to claim 1 or a salt thereof.

### Claim 12 (depends on 1)

An anticancer agent comprising the compound according to claim 1 or a salt thereof.

### Claim 13 (depends on 1)

The compound according to claim 1 or a salt thereof, which is suitable for the prevention or treatment of a disease involving HSP90.

### Claim 14 (depends on 1)

The compound according to claim 1 or a salt thereof, which is suitable for the prevention or treatment of cancer.

### Claim at position 15

15-16. (canceled)

### Claim 17 (depends on 1)

A method for preventing or treating a disease involving HSP90, comprising administering an effective amount of the compound according to claim 1 or a salt thereof to a patient in need thereof.

### Claim 18 (depends on 1)

A method for preventing or treating cancer, comprising administering the compound according to claim 1 or a salt thereof to a patient in need thereof.
